Drug intelligence / Profile preview

ginsenoside rh2

Development stage
Preclinical
Lead developer
Shanghai Pharm Valley
Modality
Small Molecules
Administration
Oral
01

Overview

Ginsenoside Rh2 is a natural triterpene saponin compound derived from Panax ginseng. It exists as two stereoisomers—20(S)-ginsenoside Rh2 and 20(R)-ginsenoside Rh2—with the S-form generally exhibiting stronger biological activity. Ginsenoside Rh2 has demonstrated potent anticancer and anti-inflammatory effects in preclinical studies. Its mechanisms of action include modulation of multiple signaling pathways such as PI3K/Akt/mTOR, Src/Raf/ERK, PDZ-binding kinase/T-LAK cell-originated protein kinase, epidermal growth factor receptor (EGFR), p53 activation, caspase-3 induction (apoptosis), and regulation of reactive oxygen species. It can induce apoptosis and cell cycle arrest in cancer cells and modulate immune responses by activating T lymphocytes. Ginsenoside Rh2 has shown efficacy against various cancers including breast cancer, colorectal cancer, hepatocellular carcinoma, gastric cancer, oral cancer, leukemia (T-ALL), melanoma models in animals as well as nonmalignant diseases like ulcerative colitis and depression[1][5][6]. Despite promising results in vitro and animal models with low toxicity profiles reported so far[1], its clinical development is limited by poor oral bioavailability[1]. No major pharmaceutical company or brand name product is currently associated with this compound.

Other names
ginsenoside-Rh2ginsenoside-Rh-2ginsenoside-Rh 2GRh2GRh-2GRh 2
02

Targets

CK1α (Casein kinase I alpha)ND1 (Mitochondrial electron transport chain complex I)bc1 complex (Cytochrome bc1 complex (plasmodium))ATP SynthaseCASP3 (Caspase-3)EGFR (Epidermal growth factor receptor)MAPK3 (Mitogen-activated protein kinase 1)mTOR (Mammalian target of rapamycin kinase)MLKL (Mixed lineage kinase domain-like protein)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)AKT (RAC-alpha serine/threonine-protein kinase)RAF1 (c-Raf-1 (Y340D/Y341D))SRC (Proto-oncogene tyrosine-protein kinase Src)TP53 (Cellular Tumor Antigen p53 R175H)

Beyond the preview

Go deeper on ginsenoside rh2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ginsenoside rh2.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call